We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Highlights Cutting-Edge Diagnostic Products and Solutions

By LabMedica International staff writers
Posted on 23 Jul 2023

Randox Laboratories (Crumlin, UK) is exhibiting its cutting-edge diagnostic products and solutions at 2023 AACC, while also highlighting its groundbreaking technologies. More...

As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including quality control, molecular diagnostics, third-party reagents, point of care, and clinical chemistry analyzers. With an extensive product range offering expansive third-party quality controls and calibrators, inter-laboratory data management, external quality assessments, and calibration verification. Randox’s new Acusera Quality Controls for 2022/2023 highlighted at the show include Active B12, Anti Mullerian Hormone (AMH), Brain Natriuretic Peptide (BNP) Control, Bone Markers (Serum) Control, Pre-eclampsia Control, Serum Indices Control, Ultra-Low PSA Control, Xanthochromia Control.

At AACC 2023, Randox is also showcasing its recently launched and the world’s first Xylazine ELISA. Xylazine, which is an analgesic drug primarily used within the veterinary industry as a tranquilizer, has not been approved for human use but has been linked to the USA’s illicit drug supply in recent years. While the prevalence of Xylazine is showing no sign of decreasing, Randox Toxicology continues to lead in new test development within the ever-changing drugs of abuse market. The company’s newly-established test for xylazine is the first immunoassay test in the world for this drug of abuse and is available on the Evidence MultiSTAT analyzer. Evidence MultiSTAT is designed to work across a variety of matrices including blood, and oral fluid, and simultaneously screens for up to 29 drugs of abuse from a single sample in less than 31 minutes.

In recent years, Randox has been expanding its Randox Health testing – bringing preventative healthcare directly to the public. Specializing in ‘Pre-disease’ highly sensitive biomarkers in the blood are measured before an individual start to feel sick and before regular blood tests would show illness. After making the service available throughout the UK and Ireland via its innovative mobile health clinic, Randox is now unveiling Randox Health Labs located in Santa Monica, California at AACC 2023. Randox’s extensive test menu offers over 150 analytes, allowing access some of the most specialized tests available in the market today.

Related Links:
Randox Laboratories 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
All-in-One Molecular System
AIO M160
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.